Wise passes both primary endpoints, page-13

Market reaction was very exciting early, bit less so now. A little disappointing to be honest.

Maybe that transmitter issue took some of the shine off, although the caompany seems pretty blase about it. Then maybe the whole timing of medical journal publication, FDA etc has led to some selling.
It is difficult to put a share price chart against these milestones. Like 25% for this clinical success, 25% for peer review in a journal, 150% for FDA approval...who knows?

I'm sort of pleased it hasn't gone completely bananas. At around $1 it gives prospective investors a chance to get on board and drive it to the next level. We need institutional buying and they could have felt they missed it if the price had punched thru to $1.30+ (I used to be one).

In short, great result, not totally unexpected hence the recent rally. Maybe if we base this rally off a 70c level then we have had a 40-50% rally on this positive news.

Good luck to all. I aint selling a share.